Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Complete Blood Count Risk Score Predict Life Expectancy

By LabMedica International staff writers
Posted on 05 Dec 2013
A simple blood test may predict who is at the highest risk to develop heart problems and how long these people may have to live. More...


The complete blood count (CBC) risk score is an inexpensive tool that uses all of the information in the common blood test, which includes laboratory data that is frequently underused.

Scientists at the Intermountain Medical Center Heart Institute (Murray, UT, USA) collaborating with those at Brigham and Women's Hospital (Boston, MA, USA) used CBC laboratory testing information gathered as part of the Justification for the Use of Statins in Primary Prevention (JUPITER) Trial, a randomized clinical trial of a cholesterol-lowering drug.

The JUPITER study enrolled more than 17,000 individuals in 26 countries and followed them for up to five years. Participants in JUPITER had a clean slate free of cardiovascular disease normal low-density-lipoprotein cholesterol, but elevated C-reactive protein, a marker of inflammation associated with cardiovascular disease.

Individuals in the trial with a lower CBC risk score were very unlikely to die, while those with CBC risk scores in the middle of the range had more than 50% higher risk of death. People with the highest CBC risk scores were about twice as likely to die as those with low scores. The CBC risk score and its parent risk score, the Intermountain Risk Score, which is a combination of the CBC laboratory test and the basic metabolic profile blood test, were created to provide useful health information to allow physicians to easily compute the risk score while continuing to care for patients.

Benjamin Horne, PhD, director of cardiovascular and genetic epidemiology at the Intermountain Medical Center, said, “We now have a standardized way of assessing the risk of mortality for all individuals, not just ones with a history of heart diseases. One of the beauties of this score is it uses clinically familiar, standardized medical information already in electronic format. The financial cost is also almost zero because most patients already receive the CBC test. The clinical cost is also low, because of electronic medical records. Physicians receive this critical information about future risk, which adds to their knowledge about the patient, while it takes very little of their time or effort to obtain the information.” The study was presented at the American Heart Association Scientific Sessions, held November 16-20, 2013, in Dallas (TX, USA. 

Related Links:
Intermountain Medical Center Heart Institute
Brigham and Women's Hospital 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.